Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2701-2720 of 3,900 trials

Mitapivat for Children with Pyruvate Kinase Deficiency

We are studying whether Mitapivat can help increase hemoglobin levels in children with Pyruvate Kinase Deficiency who do not receive regular blood transfusions. This trial compares the treatment to a placebo to assess its effectiveness.

Pyruvate Kinase Deficiency Anemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteHematologyPediatrics

Chronic Cough: Taplucainium Inhalation Powder

We are studying a new inhalation powder for adults with chronic cough that hasn't improved with other treatments. The trial will evaluate its effects on cough frequency and quality of life compared to a placebo.

Refractory or Unexplained Chronic Cough3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Blood Cancers: AZD0486 Treatment Study

We are investigating whether AZD0486, alone or with other cancer drugs, is safe and effective for adults with certain blood cancers. This includes conditions like chronic lymphocytic leukemia and large B-cell lymphoma.

Mantle Cell LymphomaLarge B-Cell LymphomaChronic Lymphocytic LeukaemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Accelerator-based BNCT for Head and Neck Cancer

We are exploring a new treatment method for patients with head and neck carcinoma. This study aims to see if it can improve outcomes compared to standard therapies.

Head and Neck Cancer>2 yearsSafety phase (I)OncologyOtolaryngology

Alzheimer's Disease: Donepezil vs. Non-Drug Treatment

We are studying whether daily donepezil can improve thinking skills in people with Alzheimer's compared to usual non-drug care. We will also look at its effects on quality of life and other clinical measures.

Alzheimer's Disease6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesNeurology

Right Heart Failure: Dapagliflozin Study

We are investigating whether adding dapagliflozin to standard care helps patients with chronic right heart failure more than standard care alone. This study aims to improve treatment options for these patients.

Chronic Right Heart Failure6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Apalutamide with Surgery

We are studying if adding apalutamide to standard hormone therapy helps men with high-risk prostate cancer after surgery. The goal is to see if this combination improves cancer control compared to hormone therapy alone.

Metastatic Prostate Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Primary Plasma Cell Leukemia: ARI0002h CAR-T Cell Therapy

We are studying a new CAR-T cell treatment for patients newly diagnosed with primary plasma cell leukemia. The trial aims to evaluate its safety, effectiveness, and impact on quality of life.

Plasma Cell Leukaemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Infection Prevention in Joint Replacement: PREVENT-iT Study

We are studying whether different irrigation solutions and local vancomycin can lower the risk of infections after hip or knee joint replacement surgeries. This research aims to improve patient outcomes and reduce the need for additional surgeries.

Total Joint Replacement SurgeryConfirmation phase (III)Standard MedicinesInfectious DiseasesOrthopedics and Traumatology

Metoprolol for Heart Health in Duchenne Muscular Dystrophy

We are studying whether metoprolol can help prevent heart issues in boys aged 8-17 with Duchenne Muscular Dystrophy. This trial will compare its effects to a placebo alongside standard heart care.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyNeurology

Rituximab for Children with Nephrotic Syndrome

We are studying whether early treatment with rituximab helps children with idiopathic nephrotic syndrome stay in remission longer than those receiving a placebo. This trial aims to improve treatment strategies for this condition.

Nephrotic Syndrome>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesInternal MedicineNephrology

Marfan Syndrome: Valsartan for Aortic Health

We are studying whether valsartan can slow down aortic root dilatation in children and young adults with Marfan syndrome. The trial will measure changes in aortic size and related health outcomes.

Marfan SyndromeLoeys-Dietz SyndromeEhlers-Danlos Syndrome>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Levosimendan Therapy for Low Ejection Fraction Takotsubo Syndrome

We are studying whether levosimendan can help improve heart function and reduce serious health risks in patients with Takotsubo syndrome. This trial compares the medication to a placebo to see if it makes a difference.

Takotsubo Syndrome1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteCardiologyInternal Medicine

Heart Failure: Sertraline for Anxiety and Depression

We are studying whether sertraline can help reduce anxiety and depression symptoms in heart failure patients. The trial also looks at its effects on heart health and overall well-being.

Heart Failure with Preserved Ejection Fraction and Anxiety>2 yearsConfirmation phase (III)Investigational MedicinesCardiologyPsychiatry

Acute Ischemic Stroke: Mechanical Thrombectomy Study

We are studying whether adding a mechanical procedure to standard treatment helps patients with acute ischemic stroke due to large vessel blockage. The trial also examines safety and quality of life for participants.

Malignant Ischemic Stroke>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Hodgkin Lymphoma: Chemotherapy Alone Study

We are exploring whether chemotherapy alone is effective for patients with early-stage Hodgkin Lymphoma who have a good prognosis. This study aims to improve treatment options and monitor for potential relapses.

Classical Hodgkin LymphomaEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Hodgkin's Lymphoma: Nivolumab and Chemotherapy Study

We are studying a new treatment approach using nivolumab followed by chemotherapy for patients with Hodgkin's lymphoma that hasn't responded to previous therapy. The goal is to see if this combination improves treatment outcomes and safety.

Refractory Hodgkin LymphomaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Kidney Transplant: Rituximab for EBV Prevention

We are studying whether early treatment with Rituximab can help prevent EBV infections and related complications in kidney transplant recipients who are EBV negative. This research aims to improve outcomes for patients receiving organs from EBV positive donors.

Epstein-Barr Virus in Kidney Transplant Patients>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesNephrology

Breast Cancer: Nivolumab and Novel Immunotherapies

We are studying whether nivolumab, alone or with other treatments, can help achieve a complete response in early breast cancer patients before surgery. This trial also looks at safety and how well the treatment works.

Breast Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer Treatment: I-BCT-1 Study

We are exploring how genetic changes in breast tumors can help select the best treatment options for patients. This study includes patients with neoadjuvant and metastatic breast cancer to improve therapy outcomes.

Breast Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology